Inflammation and cancer: role of Annexin A1 and FPR2/ALX in proliferation and metastasis in human laryngeal squamous cell carcinoma


Autoria(s): Gastardelo, Thaís Santana; Cunha, Bianca Rodrigues da; Raposo, Luís Sérgio; Maniglia, José Victor; Cury, Patrícia Maluf; Lisoni, Flávia Cristina Rodrigues; Tajara, Eloiza Helena; Oliani, Sonia Maria
Contribuinte(s)

Universidade Estadual Paulista (UNESP)

Data(s)

27/04/2015

27/04/2015

2014

Resumo

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Processo FAPESP 2008/08187-4

The anti-inflammatory protein annexin A1 (ANXA1) has been associated with cancer progression and metastasis, suggesting its role in regulating tumor cell proliferation. We investigated the mechanism of ANXA1 interaction with formylated peptide receptor 2 (FPR2/ALX) in control, peritumoral and tumor larynx tissue samples from 20 patients, to quantitate the neutrophils and mast cells, and to evaluate the protein expression and co-localization of ANXA1/FPR2 in these inflammatory cells and laryngeal squamous cells by immunocytochemistry. In addition, we performed in vitro experiments to further investigate the functional role of ANXA1/FPR2 in the proliferation and metastasis of Hep-2 cells, a cell line from larynx epidermoid carcinoma, after treatment with ANXA12–26 (annexin A1 N-terminal-derived peptide), Boc2 (antagonist of FPR) and/or dexamethasone. Under these treatments, the level of Hep-2 cell proliferation, pro-inflammatory cytokines, ANXA1/FPR2 co-localization, and the prostaglandin signalling were analyzed using ELISA, immunocytochemistry and real-time PCR. An influx of neutrophils and degranulated mast cells was detected in tumor samples. In these inflammatory cells of peritumoral and tumor samples, ANXA1/FPR2 expression was markedly exacerbated, however, in laryngeal carcinoma cells, this expression was down-regulated. ANXA12–26 treatment reduced the proliferation of the Hep-2 cells, an effect that was blocked by Boc2, and up-regulated ANXA1/FPR2 expression. ANXA12–26 treatment also reduced the levels of pro-inflammatory cytokines and affected the expression of metalloproteinases and EP receptors, which are involved in the prostaglandin signalling. Overall, this study identified potential roles for the molecular mechanism of the ANXA1/FPR2 interaction in laryngeal cancer, including its relationship with the prostaglandin pathway, providing promising starting points for future research. ANXA1 may contribute to the regulation of tumor growth and metastasis through paracrine mechanisms that are mediated by FPR2/ALX. These data may lead to new biological targets for therapeutic intervention in human laryngeal cancer.

Formato

1-23

Identificador

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0111317

Plos One, v. 9, n. 12, p. 1-23, 2014.

1932-6203

http://hdl.handle.net/11449/122479

http://dx.doi.org/10.1371/journal.pone.0111317

ISSN1932-6203-2014-09-12-01-23.pdf

5102737730539655

Idioma(s)

eng

Relação

Plos One

Direitos

openAccess

Palavras-Chave #Annexin A1 #Inflammation
Tipo

info:eu-repo/semantics/article